FDA approves pralsetinib for RET fusion-positive non-small cell lung cancer
The agency's approval announcement covers pralsetinib for patients with RET gene fusion-positive non-small cell lung cancer.
The FDA announced approval of pralsetinib for the treatment of non-small cell lung cancer in patients whose tumors carry RET gene fusions. FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions.1
The posted source record does not include additional details such as dosing, trial data, or approval pathway. Readthrough will update this item if the FDA publishes further specifics on the approval.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.